Work

CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC

Year: 2019

Type: conference-paper

Source: Pneumologie

DOI: 10.1055/s-0039-1678250

Authors: D Christoph, S Gettinger, JT Beck, X Yang, B Telivala, D Morgensztern, V Velcheti, S Ramalingam, K Schalper, M Dajee, A Ranck, R Yang, DR Spigel

Institutions: Kliniken Essen-Mitte, Yale Cancer Center, Highlands Oncology Group, Washington University in St. Louis, Cleveland Clinic, Winship Cancer Institute, Bristol-Myers Squibb (United States), Tennessee Oncology

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2922009767

FWCI:

Cites:

Cited by:

Related to: 10